Latest News
Conference Coverage
TRANSCEND NHL trial identifies window
for CAR T expansion
SAN FRANCISCO – The study shows a correlation between certain patient characteristics and outcomes with the CAR T-cell therapy JCAR017.
Feature
Hemophilia A drug heads toward approval in Europe
The drug was approved by the U.S. Food and Drug Administration in November 2017.
Conference Coverage
ROBOT trial compares surgical approaches to esophagectomy
The robot-assisted method works for patients with resectable esophageal cancer.
From the Journals
Two biomarkers predict immunotherapy response for NSCLC
Two biomarkers were associated with poor outcomes for patients with non–small cell lung cancer who were treated with immune checkpoint inhibitors...
From the Journals
CLL Index proves accurate in predicting survival, time to treat
A meta-analysis shows that the CLL-IPI is a useful tool with chemoimmunotherapy, but data is lacking about its use with targeted therapies.
Conference Coverage
Apalutamide wins big in SPARTAN prostate cancer trial
The androgen-receptor antagonist is highly effective for treating nonmetastatic castration-resistant prostate cancer.
Conference Coverage
VIDEO: Rivaroxaban plus aspirin halves ischemic strokes
In patients with stable atherosclerotic vascular disease, treatment with low-dose rivaroxaban plus aspirin halved the incidence of ischemic...
From the Journals
ASCO expands recommendations on bone-modifying agents in myeloma
The new treatment recommendations are the first update since 2007.
From the Journals
Children with sickle cell anemia fall short on antibiotic adherence
Identify barriers to prophylactic antibiotics for sickle cell patients at the time of health care interventions.
Conference Coverage
AML immune profiles correlate with relapse-free survival
SAN FRANCISCO – Immune-enriched AML might be amenable to immunotherapy that is tailored to the bone marrow tumor microenvironment.
From the Journals
Triple therapy ups response in refractory mantle cell lymphoma
The results show that triple therapy with ibrutinib, lenalidomide, and rituximab should be evaluated in a randomized controlled trial.